Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

NCT02739997 | Completed Phase 3 Results

• 3 other identifiers: 7625A-013MK-7625A-013163275
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg for the treatment of Complicated Intra-abdominal Infections (cIAI) in Japanese participants. Efficacy will be primarily assessed by clinical response defined as complete resolution or significant improvement in signs and symptoms of the index infection.

Conditions

Intra-abdominal Infection; Complicated Intra-abdominal Infection

Outcome Measures

Primary Outcomes (3)

• Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Test of Cure (TOC)

  The percentage of participants with clinical responses (cure, failure, or indeterminate) at TOC was determined. Clinical cure was defined as "complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure is required". Clinical failure was defined as "death related to IAI at any time point; persisting or recurrent infection within the abdomen requiring additional intervention to cure; need for treatment with additional antibiotics for ongoing IAI symptoms; or post-surgical wound infection that requires additional antimicrobial therapy and/or non-routing wound care". Indeterminate was defined as "study data are not available for evaluation for any reason, including death during the study period unrelated to the index infection; or extenuating circumstances that preclude classification as cure or failure".

  Day 28 (28 days after initiating study therapy)

• Percentage of Participants With Adverse Events (AEs)

  The percentage of participants with ≥1 AEs was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

  Up to Day 42 (up to 28 days after completing study therapy)

• Percentage of Participants Discontinuing Study Drug Due to AEs

  The percentage of participants withdrawing from study therapy due to an AE was determined.

  Up to Day 14

Secondary Outcomes (6)

• Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at End Of Therapy (EOT)

  Up to Day 14

• Percentage of Participants With Clinical Response (Clinical Cure, Clinical Failure, or Indeterminate) at Late Follow-Up (LFU)

  Up to Day 42 (28 days after completing study therapy)

• Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at EOT

  Up to Day 14

• Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) at TOC

  Day 28 (28 days after initiating study therapy)

• Percentage of Participants With Microbiological Response (Eradication, Persistence, or Indeterminate) by Pathogen at EOT

  Up to Day 14

Study Arms (1)

MK-7625A + metronidazole

EXPERIMENTAL

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.

Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g); Drug: metronidazole 500 mg

Interventions

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) DRUG

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion

MK-7625A + metronidazole

metronidazole 500 mg DRUG

metronidazole 500 mg administered as an IV infusion

MK-7625A + metronidazole

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has one of the following diagnoses with evidence of intra-peritoneal infection: cholecystitis (including gangrenous cholecystitis) with rupture, perforation, or progression of the infection beyond the gallbladder wall; diverticular disease with perforation or abscess; appendiceal perforation or periappendiceal abscess; acute gastric or duodenal perforation, traumatic perforation of the intestine; peritonitis due to perforated viscus or following a prior operative procedure; or Intra-abdominal abscess (including liver and spleen).
• Has evidence of systemic infection
• Had or has plans to have surgical intervention within 24 hours of the first dose of study drug
• Has radiographic evidence of perforation or abscess if enrolled preoperatively
• Is able to have intra-abdominal specimen taken at baseline for the microbiological assessment
• Female participants of child bearing potential must not be pregnant (negative human chorionic gonadotropin test) or breastfeeding and must agree to use adequate contraception for the duration of the study and up to 35 days after the last dose of study drug
• Male participants must agree to use adequate contraception for the duration of the study and up to 75 days after the last dose of study drug

You may not qualify if:

• Has simple appendicitis; abdominal wall abscess; small bowel obstruction or ischemic bowel disease without perforation; spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; infectious mononucleosis; cystic fibrosis; or pelvic infections
• Has complicated intra-abdominal infection managed by staged abdominal repair (STAR) or open abdomen drainage
• Has had acute gastric or duodenal perforation (≤ 24 hours after) or traumatic perforation of the intestine (≤ 12 hours after) operated on after the perforation occurred
• Is expected to be cured by only surgical intervention without use of systemic antibacterial therapy
• Has used systemic antibacterial therapy for intra-abdominal infection for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy
• Has severe impairment of renal function (estimated CrCl \< 30 mL/minute), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (\< 20 mL/hour urine output over 24 hours)
• Has a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to study drug with the exception of an antibacterial with Gram-positive activity only (vancomycin, teicoplanin, linezolid and daptomycin)
• Has used any postoperative non-study antibacterial therapy if enrolled preoperatively
• Has used more than 1 dose of non-study antibacterial therapy following surgery if enrolled postoperatively
• Has hepatic disease
• Is unlikely to survive the 4 to 5 week study period
• Has organic brain or spinal cord disease
• Has any rapidly-progressing disease or immediately life-threatening illness
• Has an immunocompromising condition (i.e., AIDS, hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy) or is receiving ≥ 40 mg of prednisone per day administered continuously for \> 14 days prior to study start
• Has a history of any moderate or severe hypersensitivity or allergic reaction to any beta-lactam (β-lactam) antibacterial, including cephalosporins, carbapenems, penicillins, or β-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (2)

• Li Z, Kang Y, Gao H, Zhao Y, Luo D, Wang D, Zhang X, Yu J, Chu G, Cao J, Wang F, Zhao X, Jensen E, Lin G, Chen G. Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections. Infect Dis (Lond). 2026 Jan;58(1):40-51. doi: 10.1080/23744235.2025.2544828. Epub 2025 Sep 6.

  PMID: 40913503 DERIVED

• Mikamo H, Monden K, Miyasaka Y, Horiuchi T, Fujimoto G, Fukuhara T, Yoshinari T, Rhee EG, Shizuya T. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections. J Infect Chemother. 2019 Feb;25(2):111-116. doi: 10.1016/j.jiac.2018.10.012. Epub 2018 Dec 6.

  PMID: 30528561 DERIVED

MeSH Terms

Conditions

Intraabdominal Infections

Interventions

ceftolozane; Tazobactam; Metronidazole

Condition Hierarchy (Ancestors)

Infections

Intervention Hierarchy (Ancestors)

Penicillanic Acid; Penicillins; beta-Lactams; Lactams; Amides; Organic Chemicals; Sulfur Compounds; Sulfones; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nitroimidazoles; Nitro Compounds; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring

Results Point of Contact

• Title: Senior Vice President, Global Clinical Development
• Organization: Merck Sharp & Dohme Corp.

ClinicalTrialsDisclosure@merck.com

1-800-672-6372

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2016
• First Posted: April 15, 2016
• Study Start: April 8, 2016
• Primary Completion: July 28, 2017
• Study Completion: July 28, 2017
• Last Updated: August 9, 2018
• Results First Posted: July 12, 2018

Record last verified: 2018-07

Data Sharing

• IPD Sharing: Will share